nodes	percent_of_prediction	percent_of_DWPC	metapath
Celecoxib—PTGS2—urinary bladder cancer	0.256	1	CbGaD
Celecoxib—ABCC4—Fluorouracil—urinary bladder cancer	0.073	0.243	CbGbCtD
Celecoxib—ABCC4—Methotrexate—urinary bladder cancer	0.0403	0.134	CbGbCtD
Celecoxib—PTGS2—Cisplatin—urinary bladder cancer	0.0365	0.121	CbGbCtD
Celecoxib—PTGS2—Etoposide—urinary bladder cancer	0.0358	0.119	CbGbCtD
Celecoxib—ALB—Fluorouracil—urinary bladder cancer	0.0271	0.0902	CbGbCtD
Celecoxib—CYP3A4—Thiotepa—urinary bladder cancer	0.0261	0.087	CbGbCtD
Celecoxib—ALB—Methotrexate—urinary bladder cancer	0.0149	0.0497	CbGbCtD
Celecoxib—CYP2C9—Fluorouracil—urinary bladder cancer	0.0146	0.0486	CbGbCtD
Celecoxib—CYP2C9—Cisplatin—urinary bladder cancer	0.0124	0.0413	CbGbCtD
Celecoxib—CYP2D6—Doxorubicin—urinary bladder cancer	0.0076	0.0253	CbGbCtD
Celecoxib—CYP3A4—Etoposide—urinary bladder cancer	0.00708	0.0236	CbGbCtD
Celecoxib—PDPK1—prostate gland—urinary bladder cancer	0.00521	0.0671	CbGeAlD
Celecoxib—CYP3A4—Doxorubicin—urinary bladder cancer	0.00483	0.0161	CbGbCtD
Celecoxib—PDPK1—renal system—urinary bladder cancer	0.00355	0.0457	CbGeAlD
Celecoxib—PDPK1—female reproductive system—urinary bladder cancer	0.00285	0.0366	CbGeAlD
Celecoxib—MAPK14—prostate gland—urinary bladder cancer	0.00279	0.0359	CbGeAlD
Celecoxib—CA14—prostate gland—urinary bladder cancer	0.00271	0.0349	CbGeAlD
Celecoxib—CA5A—female reproductive system—urinary bladder cancer	0.00267	0.0344	CbGeAlD
Celecoxib—PDPK1—vagina—urinary bladder cancer	0.00257	0.0331	CbGeAlD
Celecoxib—CYP2C9—urine—urinary bladder cancer	0.00256	0.0329	CbGeAlD
Celecoxib—CA14—seminal vesicle—urinary bladder cancer	0.00229	0.0295	CbGeAlD
Celecoxib—MAPK14—epithelium—urinary bladder cancer	0.00205	0.0264	CbGeAlD
Celecoxib—MAPK14—smooth muscle tissue—urinary bladder cancer	0.00197	0.0254	CbGeAlD
Celecoxib—CYP3A4—urine—urinary bladder cancer	0.00195	0.0251	CbGeAlD
Celecoxib—CYP2D6—urine—urinary bladder cancer	0.00192	0.0247	CbGeAlD
Celecoxib—MAPK14—renal system—urinary bladder cancer	0.0019	0.0244	CbGeAlD
Celecoxib—CA5B—prostate gland—urinary bladder cancer	0.0019	0.0244	CbGeAlD
Celecoxib—ORM1—prostate gland—urinary bladder cancer	0.00168	0.0216	CbGeAlD
Celecoxib—PDPK1—lymph node—urinary bladder cancer	0.00167	0.0214	CbGeAlD
Celecoxib—CA9—female reproductive system—urinary bladder cancer	0.00156	0.0201	CbGeAlD
Celecoxib—MAPK14—female reproductive system—urinary bladder cancer	0.00152	0.0196	CbGeAlD
Celecoxib—CA12—renal system—urinary bladder cancer	0.00144	0.0185	CbGeAlD
Celecoxib—ABCC4—prostate gland—urinary bladder cancer	0.00143	0.0183	CbGeAlD
Celecoxib—MAPK14—vagina—urinary bladder cancer	0.00138	0.0177	CbGeAlD
Celecoxib—CA4—prostate gland—urinary bladder cancer	0.00131	0.0169	CbGeAlD
Celecoxib—CA5B—urethra—urinary bladder cancer	0.00127	0.0163	CbGeAlD
Celecoxib—CA12—female reproductive system—urinary bladder cancer	0.00115	0.0149	CbGeAlD
Celecoxib—CA4—seminal vesicle—urinary bladder cancer	0.00111	0.0143	CbGeAlD
Celecoxib—CA2—prostate gland—urinary bladder cancer	0.00109	0.014	CbGeAlD
Celecoxib—CA5B—female reproductive system—urinary bladder cancer	0.00104	0.0133	CbGeAlD
Celecoxib—ABCC4—renal system—urinary bladder cancer	0.000971	0.0125	CbGeAlD
Celecoxib—CA5B—vagina—urinary bladder cancer	0.000937	0.0121	CbGeAlD
Celecoxib—CA2—seminal vesicle—urinary bladder cancer	0.000919	0.0118	CbGeAlD
Celecoxib—ORM1—female reproductive system—urinary bladder cancer	0.000916	0.0118	CbGeAlD
Celecoxib—CA4—renal system—urinary bladder cancer	0.000893	0.0115	CbGeAlD
Celecoxib—MAPK14—lymph node—urinary bladder cancer	0.000891	0.0115	CbGeAlD
Celecoxib—CA4—urethra—urinary bladder cancer	0.000877	0.0113	CbGeAlD
Celecoxib—Etoricoxib—PTGS2—urinary bladder cancer	0.000858	1	CrCbGaD
Celecoxib—PTGS2—prostate gland—urinary bladder cancer	0.000802	0.0103	CbGeAlD
Celecoxib—CA2—epithelium—urinary bladder cancer	0.000798	0.0103	CbGeAlD
Celecoxib—ABCC4—female reproductive system—urinary bladder cancer	0.000778	0.01	CbGeAlD
Celecoxib—CA2—smooth muscle tissue—urinary bladder cancer	0.000769	0.00989	CbGeAlD
Celecoxib—CA2—renal system—urinary bladder cancer	0.00074	0.00952	CbGeAlD
Celecoxib—CA4—female reproductive system—urinary bladder cancer	0.000715	0.0092	CbGeAlD
Celecoxib—PTGS2—seminal vesicle—urinary bladder cancer	0.000678	0.00872	CbGeAlD
Celecoxib—CA5B—lymph node—urinary bladder cancer	0.000606	0.0078	CbGeAlD
Celecoxib—CA2—female reproductive system—urinary bladder cancer	0.000593	0.00763	CbGeAlD
Celecoxib—PTGS2—epithelium—urinary bladder cancer	0.000589	0.00758	CbGeAlD
Celecoxib—PTGS2—smooth muscle tissue—urinary bladder cancer	0.000568	0.0073	CbGeAlD
Celecoxib—PTGS2—renal system—urinary bladder cancer	0.000547	0.00703	CbGeAlD
Celecoxib—PTGS2—urethra—urinary bladder cancer	0.000537	0.00691	CbGeAlD
Celecoxib—CA2—vagina—urinary bladder cancer	0.000536	0.0069	CbGeAlD
Celecoxib—ORM1—lymph node—urinary bladder cancer	0.000536	0.0069	CbGeAlD
Celecoxib—CYP2C9—female reproductive system—urinary bladder cancer	0.000502	0.00645	CbGeAlD
Celecoxib—CYP3A4—renal system—urinary bladder cancer	0.000478	0.00614	CbGeAlD
Celecoxib—ALB—lymph node—urinary bladder cancer	0.00047	0.00605	CbGeAlD
Celecoxib—CYP2D6—renal system—urinary bladder cancer	0.00047	0.00605	CbGeAlD
Celecoxib—ABCC4—lymph node—urinary bladder cancer	0.000455	0.00585	CbGeAlD
Celecoxib—PTGS2—female reproductive system—urinary bladder cancer	0.000438	0.00563	CbGeAlD
Celecoxib—CA4—lymph node—urinary bladder cancer	0.000418	0.00538	CbGeAlD
Celecoxib—PTGS2—vagina—urinary bladder cancer	0.000396	0.00509	CbGeAlD
Celecoxib—CYP3A4—female reproductive system—urinary bladder cancer	0.000383	0.00492	CbGeAlD
Celecoxib—CYP2D6—female reproductive system—urinary bladder cancer	0.000376	0.00484	CbGeAlD
Celecoxib—CA2—lymph node—urinary bladder cancer	0.000347	0.00446	CbGeAlD
Celecoxib—PTGS2—lymph node—urinary bladder cancer	0.000256	0.00329	CbGeAlD
Celecoxib—Diarrhoea—Gemcitabine—urinary bladder cancer	8.95e-05	0.000416	CcSEcCtD
Celecoxib—Erythema multiforme—Methotrexate—urinary bladder cancer	8.9e-05	0.000414	CcSEcCtD
Celecoxib—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	8.9e-05	0.000414	CcSEcCtD
Celecoxib—Urticaria—Etoposide—urinary bladder cancer	8.87e-05	0.000412	CcSEcCtD
Celecoxib—Haemoglobin—Epirubicin—urinary bladder cancer	8.85e-05	0.000412	CcSEcCtD
Celecoxib—Stomatitis—Doxorubicin—urinary bladder cancer	8.85e-05	0.000412	CcSEcCtD
Celecoxib—Jaundice—Doxorubicin—urinary bladder cancer	8.85e-05	0.000412	CcSEcCtD
Celecoxib—Rhinitis—Epirubicin—urinary bladder cancer	8.83e-05	0.000411	CcSEcCtD
Celecoxib—Abdominal pain—Etoposide—urinary bladder cancer	8.83e-05	0.00041	CcSEcCtD
Celecoxib—Body temperature increased—Etoposide—urinary bladder cancer	8.83e-05	0.00041	CcSEcCtD
Celecoxib—Urinary tract infection—Doxorubicin—urinary bladder cancer	8.83e-05	0.00041	CcSEcCtD
Celecoxib—Conjunctivitis—Doxorubicin—urinary bladder cancer	8.83e-05	0.00041	CcSEcCtD
Celecoxib—Hepatitis—Epirubicin—urinary bladder cancer	8.81e-05	0.00041	CcSEcCtD
Celecoxib—Haemorrhage—Epirubicin—urinary bladder cancer	8.81e-05	0.00041	CcSEcCtD
Celecoxib—Eye disorder—Methotrexate—urinary bladder cancer	8.8e-05	0.000409	CcSEcCtD
Celecoxib—Diarrhoea—Fluorouracil—urinary bladder cancer	8.8e-05	0.000409	CcSEcCtD
Celecoxib—Tinnitus—Methotrexate—urinary bladder cancer	8.78e-05	0.000408	CcSEcCtD
Celecoxib—Hypoaesthesia—Epirubicin—urinary bladder cancer	8.76e-05	0.000408	CcSEcCtD
Celecoxib—Asthenia—Cisplatin—urinary bladder cancer	8.74e-05	0.000407	CcSEcCtD
Celecoxib—Pharyngitis—Epirubicin—urinary bladder cancer	8.74e-05	0.000407	CcSEcCtD
Celecoxib—Cardiac disorder—Methotrexate—urinary bladder cancer	8.74e-05	0.000406	CcSEcCtD
Celecoxib—Urinary tract disorder—Epirubicin—urinary bladder cancer	8.7e-05	0.000404	CcSEcCtD
Celecoxib—Oedema peripheral—Epirubicin—urinary bladder cancer	8.68e-05	0.000403	CcSEcCtD
Celecoxib—Haematuria—Doxorubicin—urinary bladder cancer	8.66e-05	0.000403	CcSEcCtD
Celecoxib—Connective tissue disorder—Epirubicin—urinary bladder cancer	8.66e-05	0.000402	CcSEcCtD
Celecoxib—Urethral disorder—Epirubicin—urinary bladder cancer	8.64e-05	0.000402	CcSEcCtD
Celecoxib—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	8.59e-05	0.000399	CcSEcCtD
Celecoxib—Epistaxis—Doxorubicin—urinary bladder cancer	8.56e-05	0.000398	CcSEcCtD
Celecoxib—Angiopathy—Methotrexate—urinary bladder cancer	8.54e-05	0.000397	CcSEcCtD
Celecoxib—Sinusitis—Doxorubicin—urinary bladder cancer	8.52e-05	0.000396	CcSEcCtD
Celecoxib—Immune system disorder—Methotrexate—urinary bladder cancer	8.5e-05	0.000395	CcSEcCtD
Celecoxib—Dizziness—Fluorouracil—urinary bladder cancer	8.5e-05	0.000395	CcSEcCtD
Celecoxib—Mediastinal disorder—Methotrexate—urinary bladder cancer	8.48e-05	0.000394	CcSEcCtD
Celecoxib—Agranulocytosis—Doxorubicin—urinary bladder cancer	8.47e-05	0.000394	CcSEcCtD
Celecoxib—Diarrhoea—Cisplatin—urinary bladder cancer	8.34e-05	0.000388	CcSEcCtD
Celecoxib—Erythema multiforme—Epirubicin—urinary bladder cancer	8.33e-05	0.000387	CcSEcCtD
Celecoxib—Alopecia—Methotrexate—urinary bladder cancer	8.32e-05	0.000387	CcSEcCtD
Celecoxib—Vomiting—Gemcitabine—urinary bladder cancer	8.31e-05	0.000387	CcSEcCtD
Celecoxib—Mental disorder—Methotrexate—urinary bladder cancer	8.25e-05	0.000383	CcSEcCtD
Celecoxib—Rash—Gemcitabine—urinary bladder cancer	8.24e-05	0.000383	CcSEcCtD
Celecoxib—Dermatitis—Gemcitabine—urinary bladder cancer	8.24e-05	0.000383	CcSEcCtD
Celecoxib—Eye disorder—Epirubicin—urinary bladder cancer	8.23e-05	0.000383	CcSEcCtD
Celecoxib—Hypersensitivity—Etoposide—urinary bladder cancer	8.23e-05	0.000382	CcSEcCtD
Celecoxib—Tinnitus—Epirubicin—urinary bladder cancer	8.21e-05	0.000382	CcSEcCtD
Celecoxib—Haemoglobin—Doxorubicin—urinary bladder cancer	8.19e-05	0.000381	CcSEcCtD
Celecoxib—Headache—Gemcitabine—urinary bladder cancer	8.19e-05	0.000381	CcSEcCtD
Celecoxib—Cardiac disorder—Epirubicin—urinary bladder cancer	8.18e-05	0.00038	CcSEcCtD
Celecoxib—Flushing—Epirubicin—urinary bladder cancer	8.18e-05	0.00038	CcSEcCtD
Celecoxib—Vomiting—Fluorouracil—urinary bladder cancer	8.17e-05	0.00038	CcSEcCtD
Celecoxib—Rhinitis—Doxorubicin—urinary bladder cancer	8.17e-05	0.00038	CcSEcCtD
Celecoxib—Haemorrhage—Doxorubicin—urinary bladder cancer	8.15e-05	0.000379	CcSEcCtD
Celecoxib—Hepatitis—Doxorubicin—urinary bladder cancer	8.15e-05	0.000379	CcSEcCtD
Celecoxib—Hypoaesthesia—Doxorubicin—urinary bladder cancer	8.11e-05	0.000377	CcSEcCtD
Celecoxib—Rash—Fluorouracil—urinary bladder cancer	8.11e-05	0.000377	CcSEcCtD
Celecoxib—Dermatitis—Fluorouracil—urinary bladder cancer	8.1e-05	0.000377	CcSEcCtD
Celecoxib—Pharyngitis—Doxorubicin—urinary bladder cancer	8.09e-05	0.000376	CcSEcCtD
Celecoxib—Headache—Fluorouracil—urinary bladder cancer	8.05e-05	0.000374	CcSEcCtD
Celecoxib—Urinary tract disorder—Doxorubicin—urinary bladder cancer	8.05e-05	0.000374	CcSEcCtD
Celecoxib—Oedema peripheral—Doxorubicin—urinary bladder cancer	8.03e-05	0.000373	CcSEcCtD
Celecoxib—Dysgeusia—Methotrexate—urinary bladder cancer	8.02e-05	0.000373	CcSEcCtD
Celecoxib—Asthenia—Etoposide—urinary bladder cancer	8.01e-05	0.000372	CcSEcCtD
Celecoxib—Connective tissue disorder—Doxorubicin—urinary bladder cancer	8.01e-05	0.000372	CcSEcCtD
Celecoxib—Angiopathy—Epirubicin—urinary bladder cancer	7.99e-05	0.000372	CcSEcCtD
Celecoxib—Urethral disorder—Doxorubicin—urinary bladder cancer	7.99e-05	0.000372	CcSEcCtD
Celecoxib—Immune system disorder—Epirubicin—urinary bladder cancer	7.96e-05	0.00037	CcSEcCtD
Celecoxib—Mediastinal disorder—Epirubicin—urinary bladder cancer	7.94e-05	0.000369	CcSEcCtD
Celecoxib—Back pain—Methotrexate—urinary bladder cancer	7.93e-05	0.000369	CcSEcCtD
Celecoxib—Pruritus—Etoposide—urinary bladder cancer	7.9e-05	0.000367	CcSEcCtD
Celecoxib—Arrhythmia—Epirubicin—urinary bladder cancer	7.87e-05	0.000366	CcSEcCtD
Celecoxib—Alopecia—Epirubicin—urinary bladder cancer	7.78e-05	0.000362	CcSEcCtD
Celecoxib—Nausea—Gemcitabine—urinary bladder cancer	7.77e-05	0.000361	CcSEcCtD
Celecoxib—Vomiting—Cisplatin—urinary bladder cancer	7.75e-05	0.00036	CcSEcCtD
Celecoxib—Vision blurred—Methotrexate—urinary bladder cancer	7.72e-05	0.000359	CcSEcCtD
Celecoxib—Mental disorder—Epirubicin—urinary bladder cancer	7.72e-05	0.000359	CcSEcCtD
Celecoxib—Erythema multiforme—Doxorubicin—urinary bladder cancer	7.71e-05	0.000358	CcSEcCtD
Celecoxib—Rash—Cisplatin—urinary bladder cancer	7.68e-05	0.000357	CcSEcCtD
Celecoxib—Dermatitis—Cisplatin—urinary bladder cancer	7.68e-05	0.000357	CcSEcCtD
Celecoxib—Diarrhoea—Etoposide—urinary bladder cancer	7.64e-05	0.000355	CcSEcCtD
Celecoxib—Nausea—Fluorouracil—urinary bladder cancer	7.64e-05	0.000355	CcSEcCtD
Celecoxib—Eye disorder—Doxorubicin—urinary bladder cancer	7.62e-05	0.000354	CcSEcCtD
Celecoxib—Tinnitus—Doxorubicin—urinary bladder cancer	7.6e-05	0.000353	CcSEcCtD
Celecoxib—Anaemia—Methotrexate—urinary bladder cancer	7.57e-05	0.000352	CcSEcCtD
Celecoxib—Cardiac disorder—Doxorubicin—urinary bladder cancer	7.56e-05	0.000352	CcSEcCtD
Celecoxib—Flushing—Doxorubicin—urinary bladder cancer	7.56e-05	0.000352	CcSEcCtD
Celecoxib—Flatulence—Epirubicin—urinary bladder cancer	7.56e-05	0.000351	CcSEcCtD
Celecoxib—Tension—Epirubicin—urinary bladder cancer	7.52e-05	0.00035	CcSEcCtD
Celecoxib—Dysgeusia—Epirubicin—urinary bladder cancer	7.51e-05	0.000349	CcSEcCtD
Celecoxib—Nervousness—Epirubicin—urinary bladder cancer	7.45e-05	0.000346	CcSEcCtD
Celecoxib—Back pain—Epirubicin—urinary bladder cancer	7.42e-05	0.000345	CcSEcCtD
Celecoxib—Angiopathy—Doxorubicin—urinary bladder cancer	7.39e-05	0.000344	CcSEcCtD
Celecoxib—Dizziness—Etoposide—urinary bladder cancer	7.38e-05	0.000343	CcSEcCtD
Celecoxib—Muscle spasms—Epirubicin—urinary bladder cancer	7.37e-05	0.000343	CcSEcCtD
Celecoxib—Immune system disorder—Doxorubicin—urinary bladder cancer	7.36e-05	0.000342	CcSEcCtD
Celecoxib—Vertigo—Methotrexate—urinary bladder cancer	7.36e-05	0.000342	CcSEcCtD
Celecoxib—Mediastinal disorder—Doxorubicin—urinary bladder cancer	7.35e-05	0.000342	CcSEcCtD
Celecoxib—Leukopenia—Methotrexate—urinary bladder cancer	7.33e-05	0.000341	CcSEcCtD
Celecoxib—Arrhythmia—Doxorubicin—urinary bladder cancer	7.28e-05	0.000339	CcSEcCtD
Celecoxib—Nausea—Cisplatin—urinary bladder cancer	7.24e-05	0.000337	CcSEcCtD
Celecoxib—Vision blurred—Epirubicin—urinary bladder cancer	7.23e-05	0.000336	CcSEcCtD
Celecoxib—Alopecia—Doxorubicin—urinary bladder cancer	7.2e-05	0.000335	CcSEcCtD
Celecoxib—Cough—Methotrexate—urinary bladder cancer	7.15e-05	0.000332	CcSEcCtD
Celecoxib—Mental disorder—Doxorubicin—urinary bladder cancer	7.14e-05	0.000332	CcSEcCtD
Celecoxib—Vomiting—Etoposide—urinary bladder cancer	7.1e-05	0.00033	CcSEcCtD
Celecoxib—Anaemia—Epirubicin—urinary bladder cancer	7.09e-05	0.00033	CcSEcCtD
Celecoxib—Rash—Etoposide—urinary bladder cancer	7.04e-05	0.000327	CcSEcCtD
Celecoxib—Dermatitis—Etoposide—urinary bladder cancer	7.03e-05	0.000327	CcSEcCtD
Celecoxib—Headache—Etoposide—urinary bladder cancer	6.99e-05	0.000325	CcSEcCtD
Celecoxib—Flatulence—Doxorubicin—urinary bladder cancer	6.99e-05	0.000325	CcSEcCtD
Celecoxib—Chest pain—Methotrexate—urinary bladder cancer	6.98e-05	0.000324	CcSEcCtD
Celecoxib—Arthralgia—Methotrexate—urinary bladder cancer	6.98e-05	0.000324	CcSEcCtD
Celecoxib—Myalgia—Methotrexate—urinary bladder cancer	6.98e-05	0.000324	CcSEcCtD
Celecoxib—Tension—Doxorubicin—urinary bladder cancer	6.96e-05	0.000324	CcSEcCtD
Celecoxib—Dysgeusia—Doxorubicin—urinary bladder cancer	6.95e-05	0.000323	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	6.93e-05	0.000322	CcSEcCtD
Celecoxib—Nervousness—Doxorubicin—urinary bladder cancer	6.89e-05	0.00032	CcSEcCtD
Celecoxib—Vertigo—Epirubicin—urinary bladder cancer	6.89e-05	0.00032	CcSEcCtD
Celecoxib—Syncope—Epirubicin—urinary bladder cancer	6.88e-05	0.00032	CcSEcCtD
Celecoxib—Leukopenia—Epirubicin—urinary bladder cancer	6.86e-05	0.000319	CcSEcCtD
Celecoxib—Back pain—Doxorubicin—urinary bladder cancer	6.86e-05	0.000319	CcSEcCtD
Celecoxib—Muscle spasms—Doxorubicin—urinary bladder cancer	6.82e-05	0.000317	CcSEcCtD
Celecoxib—Palpitations—Epirubicin—urinary bladder cancer	6.78e-05	0.000315	CcSEcCtD
Celecoxib—Confusional state—Methotrexate—urinary bladder cancer	6.74e-05	0.000314	CcSEcCtD
Celecoxib—Loss of consciousness—Epirubicin—urinary bladder cancer	6.74e-05	0.000313	CcSEcCtD
Celecoxib—Cough—Epirubicin—urinary bladder cancer	6.69e-05	0.000311	CcSEcCtD
Celecoxib—Anaphylactic shock—Methotrexate—urinary bladder cancer	6.69e-05	0.000311	CcSEcCtD
Celecoxib—Vision blurred—Doxorubicin—urinary bladder cancer	6.69e-05	0.000311	CcSEcCtD
Celecoxib—Infection—Methotrexate—urinary bladder cancer	6.64e-05	0.000309	CcSEcCtD
Celecoxib—Nausea—Etoposide—urinary bladder cancer	6.63e-05	0.000308	CcSEcCtD
Celecoxib—Hypertension—Epirubicin—urinary bladder cancer	6.62e-05	0.000308	CcSEcCtD
Celecoxib—Nervous system disorder—Methotrexate—urinary bladder cancer	6.56e-05	0.000305	CcSEcCtD
Celecoxib—Anaemia—Doxorubicin—urinary bladder cancer	6.56e-05	0.000305	CcSEcCtD
Celecoxib—Thrombocytopenia—Methotrexate—urinary bladder cancer	6.55e-05	0.000304	CcSEcCtD
Celecoxib—Myalgia—Epirubicin—urinary bladder cancer	6.53e-05	0.000304	CcSEcCtD
Celecoxib—Arthralgia—Epirubicin—urinary bladder cancer	6.53e-05	0.000304	CcSEcCtD
Celecoxib—Chest pain—Epirubicin—urinary bladder cancer	6.53e-05	0.000304	CcSEcCtD
Celecoxib—Anxiety—Epirubicin—urinary bladder cancer	6.51e-05	0.000303	CcSEcCtD
Celecoxib—Skin disorder—Methotrexate—urinary bladder cancer	6.5e-05	0.000302	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	6.48e-05	0.000301	CcSEcCtD
Celecoxib—Hyperhidrosis—Methotrexate—urinary bladder cancer	6.46e-05	0.000301	CcSEcCtD
Celecoxib—Dry mouth—Epirubicin—urinary bladder cancer	6.38e-05	0.000297	CcSEcCtD
Celecoxib—Vertigo—Doxorubicin—urinary bladder cancer	6.37e-05	0.000296	CcSEcCtD
Celecoxib—Anorexia—Methotrexate—urinary bladder cancer	6.37e-05	0.000296	CcSEcCtD
Celecoxib—Syncope—Doxorubicin—urinary bladder cancer	6.36e-05	0.000296	CcSEcCtD
Celecoxib—Leukopenia—Doxorubicin—urinary bladder cancer	6.35e-05	0.000295	CcSEcCtD
Celecoxib—Confusional state—Epirubicin—urinary bladder cancer	6.31e-05	0.000293	CcSEcCtD
Celecoxib—Palpitations—Doxorubicin—urinary bladder cancer	6.27e-05	0.000292	CcSEcCtD
Celecoxib—Anaphylactic shock—Epirubicin—urinary bladder cancer	6.26e-05	0.000291	CcSEcCtD
Celecoxib—Oedema—Epirubicin—urinary bladder cancer	6.26e-05	0.000291	CcSEcCtD
Celecoxib—Loss of consciousness—Doxorubicin—urinary bladder cancer	6.24e-05	0.00029	CcSEcCtD
Celecoxib—Infection—Epirubicin—urinary bladder cancer	6.22e-05	0.000289	CcSEcCtD
Celecoxib—Cough—Doxorubicin—urinary bladder cancer	6.19e-05	0.000288	CcSEcCtD
Celecoxib—Shock—Epirubicin—urinary bladder cancer	6.16e-05	0.000286	CcSEcCtD
Celecoxib—Nervous system disorder—Epirubicin—urinary bladder cancer	6.14e-05	0.000285	CcSEcCtD
Celecoxib—Thrombocytopenia—Epirubicin—urinary bladder cancer	6.13e-05	0.000285	CcSEcCtD
Celecoxib—Hypertension—Doxorubicin—urinary bladder cancer	6.13e-05	0.000285	CcSEcCtD
Celecoxib—Tachycardia—Epirubicin—urinary bladder cancer	6.11e-05	0.000284	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	6.09e-05	0.000283	CcSEcCtD
Celecoxib—Skin disorder—Epirubicin—urinary bladder cancer	6.08e-05	0.000283	CcSEcCtD
Celecoxib—Hyperhidrosis—Epirubicin—urinary bladder cancer	6.05e-05	0.000281	CcSEcCtD
Celecoxib—Insomnia—Methotrexate—urinary bladder cancer	6.05e-05	0.000281	CcSEcCtD
Celecoxib—Chest pain—Doxorubicin—urinary bladder cancer	6.04e-05	0.000281	CcSEcCtD
Celecoxib—Arthralgia—Doxorubicin—urinary bladder cancer	6.04e-05	0.000281	CcSEcCtD
Celecoxib—Myalgia—Doxorubicin—urinary bladder cancer	6.04e-05	0.000281	CcSEcCtD
Celecoxib—Anxiety—Doxorubicin—urinary bladder cancer	6.02e-05	0.00028	CcSEcCtD
Celecoxib—Paraesthesia—Methotrexate—urinary bladder cancer	6.01e-05	0.000279	CcSEcCtD
Celecoxib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	6e-05	0.000279	CcSEcCtD
Celecoxib—Anorexia—Epirubicin—urinary bladder cancer	5.97e-05	0.000277	CcSEcCtD
Celecoxib—Dyspnoea—Methotrexate—urinary bladder cancer	5.96e-05	0.000277	CcSEcCtD
Celecoxib—Somnolence—Methotrexate—urinary bladder cancer	5.95e-05	0.000276	CcSEcCtD
Celecoxib—Dry mouth—Doxorubicin—urinary bladder cancer	5.91e-05	0.000275	CcSEcCtD
Celecoxib—Dyspepsia—Methotrexate—urinary bladder cancer	5.89e-05	0.000274	CcSEcCtD
Celecoxib—Confusional state—Doxorubicin—urinary bladder cancer	5.84e-05	0.000271	CcSEcCtD
Celecoxib—Decreased appetite—Methotrexate—urinary bladder cancer	5.81e-05	0.00027	CcSEcCtD
Celecoxib—Anaphylactic shock—Doxorubicin—urinary bladder cancer	5.79e-05	0.000269	CcSEcCtD
Celecoxib—Oedema—Doxorubicin—urinary bladder cancer	5.79e-05	0.000269	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	5.77e-05	0.000268	CcSEcCtD
Celecoxib—Fatigue—Methotrexate—urinary bladder cancer	5.77e-05	0.000268	CcSEcCtD
Celecoxib—Infection—Doxorubicin—urinary bladder cancer	5.75e-05	0.000267	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	5.7e-05	0.000265	CcSEcCtD
Celecoxib—Shock—Doxorubicin—urinary bladder cancer	5.7e-05	0.000265	CcSEcCtD
Celecoxib—Nervous system disorder—Doxorubicin—urinary bladder cancer	5.68e-05	0.000264	CcSEcCtD
Celecoxib—Thrombocytopenia—Doxorubicin—urinary bladder cancer	5.67e-05	0.000264	CcSEcCtD
Celecoxib—Insomnia—Epirubicin—urinary bladder cancer	5.66e-05	0.000263	CcSEcCtD
Celecoxib—Tachycardia—Doxorubicin—urinary bladder cancer	5.65e-05	0.000263	CcSEcCtD
Celecoxib—Skin disorder—Doxorubicin—urinary bladder cancer	5.62e-05	0.000262	CcSEcCtD
Celecoxib—Paraesthesia—Epirubicin—urinary bladder cancer	5.62e-05	0.000261	CcSEcCtD
Celecoxib—Hyperhidrosis—Doxorubicin—urinary bladder cancer	5.6e-05	0.00026	CcSEcCtD
Celecoxib—Dyspnoea—Epirubicin—urinary bladder cancer	5.58e-05	0.000259	CcSEcCtD
Celecoxib—Somnolence—Epirubicin—urinary bladder cancer	5.56e-05	0.000259	CcSEcCtD
Celecoxib—Anorexia—Doxorubicin—urinary bladder cancer	5.52e-05	0.000257	CcSEcCtD
Celecoxib—Feeling abnormal—Methotrexate—urinary bladder cancer	5.51e-05	0.000256	CcSEcCtD
Celecoxib—Dyspepsia—Epirubicin—urinary bladder cancer	5.51e-05	0.000256	CcSEcCtD
Celecoxib—Gastrointestinal pain—Methotrexate—urinary bladder cancer	5.47e-05	0.000254	CcSEcCtD
Celecoxib—Decreased appetite—Epirubicin—urinary bladder cancer	5.44e-05	0.000253	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	5.4e-05	0.000251	CcSEcCtD
Celecoxib—Fatigue—Epirubicin—urinary bladder cancer	5.4e-05	0.000251	CcSEcCtD
Celecoxib—Constipation—Epirubicin—urinary bladder cancer	5.35e-05	0.000249	CcSEcCtD
Celecoxib—Urticaria—Methotrexate—urinary bladder cancer	5.31e-05	0.000247	CcSEcCtD
Celecoxib—Abdominal pain—Methotrexate—urinary bladder cancer	5.29e-05	0.000246	CcSEcCtD
Celecoxib—Body temperature increased—Methotrexate—urinary bladder cancer	5.29e-05	0.000246	CcSEcCtD
Celecoxib—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	5.28e-05	0.000245	CcSEcCtD
Celecoxib—Insomnia—Doxorubicin—urinary bladder cancer	5.24e-05	0.000244	CcSEcCtD
Celecoxib—Paraesthesia—Doxorubicin—urinary bladder cancer	5.2e-05	0.000242	CcSEcCtD
Celecoxib—Dyspnoea—Doxorubicin—urinary bladder cancer	5.16e-05	0.00024	CcSEcCtD
Celecoxib—Feeling abnormal—Epirubicin—urinary bladder cancer	5.16e-05	0.00024	CcSEcCtD
Celecoxib—Somnolence—Doxorubicin—urinary bladder cancer	5.15e-05	0.000239	CcSEcCtD
Celecoxib—Gastrointestinal pain—Epirubicin—urinary bladder cancer	5.12e-05	0.000238	CcSEcCtD
Celecoxib—Dyspepsia—Doxorubicin—urinary bladder cancer	5.1e-05	0.000237	CcSEcCtD
Celecoxib—Decreased appetite—Doxorubicin—urinary bladder cancer	5.03e-05	0.000234	CcSEcCtD
Celecoxib—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	5e-05	0.000232	CcSEcCtD
Celecoxib—Fatigue—Doxorubicin—urinary bladder cancer	4.99e-05	0.000232	CcSEcCtD
Celecoxib—Urticaria—Epirubicin—urinary bladder cancer	4.97e-05	0.000231	CcSEcCtD
Celecoxib—Constipation—Doxorubicin—urinary bladder cancer	4.95e-05	0.00023	CcSEcCtD
Celecoxib—Abdominal pain—Epirubicin—urinary bladder cancer	4.95e-05	0.00023	CcSEcCtD
Celecoxib—Body temperature increased—Epirubicin—urinary bladder cancer	4.95e-05	0.00023	CcSEcCtD
Celecoxib—Hypersensitivity—Methotrexate—urinary bladder cancer	4.93e-05	0.000229	CcSEcCtD
Celecoxib—Asthenia—Methotrexate—urinary bladder cancer	4.8e-05	0.000223	CcSEcCtD
Celecoxib—Feeling abnormal—Doxorubicin—urinary bladder cancer	4.77e-05	0.000222	CcSEcCtD
Celecoxib—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	4.74e-05	0.00022	CcSEcCtD
Celecoxib—Pruritus—Methotrexate—urinary bladder cancer	4.73e-05	0.00022	CcSEcCtD
Celecoxib—Hypersensitivity—Epirubicin—urinary bladder cancer	4.61e-05	0.000214	CcSEcCtD
Celecoxib—Urticaria—Doxorubicin—urinary bladder cancer	4.6e-05	0.000214	CcSEcCtD
Celecoxib—Abdominal pain—Doxorubicin—urinary bladder cancer	4.58e-05	0.000213	CcSEcCtD
Celecoxib—Body temperature increased—Doxorubicin—urinary bladder cancer	4.58e-05	0.000213	CcSEcCtD
Celecoxib—Diarrhoea—Methotrexate—urinary bladder cancer	4.58e-05	0.000213	CcSEcCtD
Celecoxib—Asthenia—Epirubicin—urinary bladder cancer	4.49e-05	0.000209	CcSEcCtD
Celecoxib—Pruritus—Epirubicin—urinary bladder cancer	4.43e-05	0.000206	CcSEcCtD
Celecoxib—Dizziness—Methotrexate—urinary bladder cancer	4.42e-05	0.000206	CcSEcCtD
Celecoxib—Diarrhoea—Epirubicin—urinary bladder cancer	4.28e-05	0.000199	CcSEcCtD
Celecoxib—Hypersensitivity—Doxorubicin—urinary bladder cancer	4.27e-05	0.000198	CcSEcCtD
Celecoxib—Vomiting—Methotrexate—urinary bladder cancer	4.25e-05	0.000198	CcSEcCtD
Celecoxib—Rash—Methotrexate—urinary bladder cancer	4.22e-05	0.000196	CcSEcCtD
Celecoxib—Dermatitis—Methotrexate—urinary bladder cancer	4.21e-05	0.000196	CcSEcCtD
Celecoxib—Headache—Methotrexate—urinary bladder cancer	4.19e-05	0.000195	CcSEcCtD
Celecoxib—Asthenia—Doxorubicin—urinary bladder cancer	4.15e-05	0.000193	CcSEcCtD
Celecoxib—Dizziness—Epirubicin—urinary bladder cancer	4.14e-05	0.000192	CcSEcCtD
Celecoxib—Pruritus—Doxorubicin—urinary bladder cancer	4.1e-05	0.00019	CcSEcCtD
Celecoxib—Vomiting—Epirubicin—urinary bladder cancer	3.98e-05	0.000185	CcSEcCtD
Celecoxib—Nausea—Methotrexate—urinary bladder cancer	3.97e-05	0.000185	CcSEcCtD
Celecoxib—Diarrhoea—Doxorubicin—urinary bladder cancer	3.96e-05	0.000184	CcSEcCtD
Celecoxib—Rash—Epirubicin—urinary bladder cancer	3.95e-05	0.000183	CcSEcCtD
Celecoxib—Dermatitis—Epirubicin—urinary bladder cancer	3.94e-05	0.000183	CcSEcCtD
Celecoxib—Headache—Epirubicin—urinary bladder cancer	3.92e-05	0.000182	CcSEcCtD
Celecoxib—Dizziness—Doxorubicin—urinary bladder cancer	3.83e-05	0.000178	CcSEcCtD
Celecoxib—Nausea—Epirubicin—urinary bladder cancer	3.72e-05	0.000173	CcSEcCtD
Celecoxib—Vomiting—Doxorubicin—urinary bladder cancer	3.68e-05	0.000171	CcSEcCtD
Celecoxib—Rash—Doxorubicin—urinary bladder cancer	3.65e-05	0.00017	CcSEcCtD
Celecoxib—Dermatitis—Doxorubicin—urinary bladder cancer	3.65e-05	0.00017	CcSEcCtD
Celecoxib—Headache—Doxorubicin—urinary bladder cancer	3.63e-05	0.000169	CcSEcCtD
Celecoxib—Nausea—Doxorubicin—urinary bladder cancer	3.44e-05	0.00016	CcSEcCtD
Celecoxib—PTGS2—Disease—RBX1—urinary bladder cancer	1.68e-05	0.000112	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—EP300—urinary bladder cancer	1.67e-05	0.000111	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.66e-05	0.000111	CbGpPWpGaD
Celecoxib—ALB—Metabolism—TYMP—urinary bladder cancer	1.66e-05	0.00011	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—EP300—urinary bladder cancer	1.66e-05	0.00011	CbGpPWpGaD
Celecoxib—CA4—Metabolism—PTGS2—urinary bladder cancer	1.66e-05	0.00011	CbGpPWpGaD
Celecoxib—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.65e-05	0.00011	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—JAG1—urinary bladder cancer	1.65e-05	0.00011	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—SRC—urinary bladder cancer	1.64e-05	0.000109	CbGpPWpGaD
Celecoxib—CA9—Metabolism—CREBBP—urinary bladder cancer	1.63e-05	0.000109	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—SRC—urinary bladder cancer	1.63e-05	0.000108	CbGpPWpGaD
Celecoxib—PDPK1—Disease—CDKN1A—urinary bladder cancer	1.62e-05	0.000108	CbGpPWpGaD
Celecoxib—PDPK1—Disease—PTEN—urinary bladder cancer	1.62e-05	0.000108	CbGpPWpGaD
Celecoxib—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	1.62e-05	0.000108	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—SRC—urinary bladder cancer	1.61e-05	0.000107	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—RRM2—urinary bladder cancer	1.6e-05	0.000107	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.59e-05	0.000106	CbGpPWpGaD
Celecoxib—CA2—Metabolism—PTGS2—urinary bladder cancer	1.59e-05	0.000106	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CREBBP—urinary bladder cancer	1.59e-05	0.000106	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—CDKN1A—urinary bladder cancer	1.57e-05	0.000104	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—IGF1—urinary bladder cancer	1.57e-05	0.000104	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—PTEN—urinary bladder cancer	1.56e-05	0.000104	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—EGFR—urinary bladder cancer	1.56e-05	0.000104	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	1.56e-05	0.000104	CbGpPWpGaD
Celecoxib—PDPK1—Disease—EP300—urinary bladder cancer	1.54e-05	0.000103	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—PLAU—urinary bladder cancer	1.52e-05	0.000102	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—KRAS—urinary bladder cancer	1.52e-05	0.000101	CbGpPWpGaD
Celecoxib—PDPK1—Disease—SRC—urinary bladder cancer	1.5e-05	0.0001	CbGpPWpGaD
Celecoxib—PTGS2—Disease—JAG1—urinary bladder cancer	1.5e-05	0.0001	CbGpPWpGaD
Celecoxib—ALB—Metabolism—NAT2—urinary bladder cancer	1.5e-05	9.98e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—FGFR3—urinary bladder cancer	1.5e-05	9.98e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—EP300—urinary bladder cancer	1.49e-05	9.93e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—ENO2—urinary bladder cancer	1.48e-05	9.87e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—HPGDS—urinary bladder cancer	1.48e-05	9.87e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	1.48e-05	9.84e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—NAT1—urinary bladder cancer	1.48e-05	9.84e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—KRAS—urinary bladder cancer	1.47e-05	9.81e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.47e-05	9.81e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—SRC—urinary bladder cancer	1.45e-05	9.66e-05	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—ESR1—urinary bladder cancer	1.45e-05	9.64e-05	CbGpPWpGaD
Celecoxib—CA4—Metabolism—PTEN—urinary bladder cancer	1.44e-05	9.62e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—EGFR—urinary bladder cancer	1.44e-05	9.59e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—GSTT1—urinary bladder cancer	1.44e-05	9.57e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—RHOA—urinary bladder cancer	1.44e-05	9.56e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—EGFR—urinary bladder cancer	1.42e-05	9.49e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.41e-05	9.42e-05	CbGpPWpGaD
Celecoxib—CA2—Metabolism—PTEN—urinary bladder cancer	1.38e-05	9.22e-05	CbGpPWpGaD
Celecoxib—CA4—Metabolism—EP300—urinary bladder cancer	1.38e-05	9.18e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—TNF—urinary bladder cancer	1.37e-05	9.13e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—TYMP—urinary bladder cancer	1.37e-05	9.12e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.36e-05	9.06e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—KRAS—urinary bladder cancer	1.36e-05	9.06e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—TYMP—urinary bladder cancer	1.36e-05	9.04e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—TP53—urinary bladder cancer	1.35e-05	9.02e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	1.35e-05	9e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—KRAS—urinary bladder cancer	1.35e-05	8.96e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—MYC—urinary bladder cancer	1.34e-05	8.96e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PTGS2—urinary bladder cancer	1.34e-05	8.92e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—KRAS—urinary bladder cancer	1.33e-05	8.88e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—S100B—urinary bladder cancer	1.33e-05	8.87e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—ERBB2—urinary bladder cancer	1.33e-05	8.85e-05	CbGpPWpGaD
Celecoxib—CA2—Metabolism—EP300—urinary bladder cancer	1.32e-05	8.8e-05	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—PPARG—urinary bladder cancer	1.32e-05	8.79e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—EGFR—urinary bladder cancer	1.32e-05	8.76e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.3e-05	8.68e-05	CbGpPWpGaD
Celecoxib—ABCC4—Hemostasis—HRAS—urinary bladder cancer	1.3e-05	8.63e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—RRM2—urinary bladder cancer	1.29e-05	8.62e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CREBBP—urinary bladder cancer	1.28e-05	8.5e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—EGFR—urinary bladder cancer	1.27e-05	8.47e-05	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—CREBBP—urinary bladder cancer	1.27e-05	8.45e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CDH1—urinary bladder cancer	1.27e-05	8.43e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CXCL8—urinary bladder cancer	1.26e-05	8.39e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—CREBBP—urinary bladder cancer	1.26e-05	8.37e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling by GPCR—HRAS—urinary bladder cancer	1.25e-05	8.34e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—KRAS—urinary bladder cancer	1.24e-05	8.28e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—IGF1—urinary bladder cancer	1.24e-05	8.27e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—NAT2—urinary bladder cancer	1.24e-05	8.24e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—NAT2—urinary bladder cancer	1.23e-05	8.17e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	1.22e-05	8.1e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—IL2—urinary bladder cancer	1.2e-05	8.02e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—KRAS—urinary bladder cancer	1.2e-05	8e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—ENO2—urinary bladder cancer	1.2e-05	7.98e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—HPGDS—urinary bladder cancer	1.2e-05	7.98e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—NCOR1—urinary bladder cancer	1.2e-05	7.98e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—NQO1—urinary bladder cancer	1.19e-05	7.95e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.19e-05	7.94e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—TP53—urinary bladder cancer	1.19e-05	7.9e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CCND1—urinary bladder cancer	1.17e-05	7.82e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—PTEN—urinary bladder cancer	1.17e-05	7.77e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GSTT1—urinary bladder cancer	1.16e-05	7.74e-05	CbGpPWpGaD
Celecoxib—MAPK14—Developmental Biology—HRAS—urinary bladder cancer	1.16e-05	7.7e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	1.15e-05	7.65e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.14e-05	7.62e-05	CbGpPWpGaD
Celecoxib—PDPK1—Immune System—HRAS—urinary bladder cancer	1.14e-05	7.62e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MMP9—urinary bladder cancer	1.14e-05	7.59e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—RHOA—urinary bladder cancer	1.14e-05	7.58e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—CDKN1A—urinary bladder cancer	1.14e-05	7.57e-05	CbGpPWpGaD
Celecoxib—MAPK14—Hemostasis—HRAS—urinary bladder cancer	1.13e-05	7.55e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—PTEN—urinary bladder cancer	1.13e-05	7.55e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	1.12e-05	7.46e-05	CbGpPWpGaD
Celecoxib—CA9—Metabolism—EP300—urinary bladder cancer	1.11e-05	7.41e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—NCOR1—urinary bladder cancer	1.09e-05	7.28e-05	CbGpPWpGaD
Celecoxib—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.09e-05	7.25e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—EP300—urinary bladder cancer	1.08e-05	7.2e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—RRM2—urinary bladder cancer	1.07e-05	7.12e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—ERBB2—urinary bladder cancer	1.07e-05	7.11e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—RRM2—urinary bladder cancer	1.06e-05	7.05e-05	CbGpPWpGaD
Celecoxib—PDPK1—Disease—HRAS—urinary bladder cancer	1.06e-05	7.04e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TERT—urinary bladder cancer	1.06e-05	7.03e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—SRC—urinary bladder cancer	1.05e-05	7e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—ERCC2—urinary bladder cancer	1.03e-05	6.84e-05	CbGpPWpGaD
Celecoxib—MAPK14—Innate Immune System—HRAS—urinary bladder cancer	1.02e-05	6.8e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.01e-05	6.73e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—GSTP1—urinary bladder cancer	9.96e-06	6.63e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	9.9e-06	6.59e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ENO2—urinary bladder cancer	9.9e-06	6.59e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ENO2—urinary bladder cancer	9.81e-06	6.53e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	9.81e-06	6.53e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	9.75e-06	6.5e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—FGFR3—urinary bladder cancer	9.69e-06	6.45e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—IL2—urinary bladder cancer	9.68e-06	6.45e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—NQO1—urinary bladder cancer	9.66e-06	6.43e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MTHFR—urinary bladder cancer	9.66e-06	6.43e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	9.63e-06	6.42e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—TERT—urinary bladder cancer	9.63e-06	6.41e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	9.6e-06	6.39e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—IL2—urinary bladder cancer	9.54e-06	6.36e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	9.51e-06	6.34e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—MYC—urinary bladder cancer	9.42e-06	6.27e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—ESR1—urinary bladder cancer	9.41e-06	6.27e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	9.37e-06	6.24e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	9.37e-06	6.24e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—TYMS—urinary bladder cancer	9.26e-06	6.17e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—EGFR—urinary bladder cancer	9.21e-06	6.14e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—NCOR1—urinary bladder cancer	9.15e-06	6.1e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—GSTM1—urinary bladder cancer	9.15e-06	6.1e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—CDKN1A—urinary bladder cancer	9.13e-06	6.08e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—PTEN—urinary bladder cancer	9.11e-06	6.07e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—TYMP—urinary bladder cancer	8.95e-06	5.96e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—FGFR3—urinary bladder cancer	8.84e-06	5.89e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—GPX1—urinary bladder cancer	8.76e-06	5.84e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—KRAS—urinary bladder cancer	8.7e-06	5.8e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—EP300—urinary bladder cancer	8.69e-06	5.79e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—ERCC2—urinary bladder cancer	8.6e-06	5.73e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—EP300—urinary bladder cancer	8.56e-06	5.7e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—SRC—urinary bladder cancer	8.45e-06	5.63e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—SRC—urinary bladder cancer	8.33e-06	5.55e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CREBBP—urinary bladder cancer	8.25e-06	5.49e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	8.17e-06	5.44e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IGF1—urinary bladder cancer	8.14e-06	5.42e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—NAT2—urinary bladder cancer	8.09e-06	5.39e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—MTHFR—urinary bladder cancer	8.09e-06	5.39e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GSTP1—urinary bladder cancer	8.06e-06	5.37e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—NQO1—urinary bladder cancer	7.98e-06	5.31e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—NQO1—urinary bladder cancer	7.91e-06	5.27e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.8e-06	5.19e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—TP53—urinary bladder cancer	7.73e-06	5.15e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	7.67e-06	5.11e-05	CbGpPWpGaD
Celecoxib—MAPK14—Gene Expression—MYC—urinary bladder cancer	7.53e-06	5.01e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CREBBP—urinary bladder cancer	7.52e-06	5.01e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—TYMS—urinary bladder cancer	7.49e-06	4.99e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—RHOA—urinary bladder cancer	7.46e-06	4.97e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—NCOR1—urinary bladder cancer	7.4e-06	4.93e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GSTM1—urinary bladder cancer	7.4e-06	4.93e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—EGFR—urinary bladder cancer	7.4e-06	4.93e-05	CbGpPWpGaD
Celecoxib—PDPK1—Signaling Pathways—HRAS—urinary bladder cancer	7.4e-06	4.93e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—GPX1—urinary bladder cancer	7.09e-06	4.72e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—KRAS—urinary bladder cancer	6.99e-06	4.66e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—RRM2—urinary bladder cancer	6.99e-06	4.65e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—ERCC2—urinary bladder cancer	6.96e-06	4.64e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—ERBB2—urinary bladder cancer	6.91e-06	4.6e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—KRAS—urinary bladder cancer	6.89e-06	4.59e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—RHOA—urinary bladder cancer	6.81e-06	4.53e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.69e-06	4.46e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	6.65e-06	4.43e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	6.59e-06	4.39e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PPARG—urinary bladder cancer	6.56e-06	4.37e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CXCL8—urinary bladder cancer	6.55e-06	4.36e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—MTHFR—urinary bladder cancer	6.54e-06	4.36e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	6.47e-06	4.31e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ENO2—urinary bladder cancer	6.47e-06	4.31e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.38e-06	4.25e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—CREBBP—urinary bladder cancer	6.3e-06	4.2e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—ERBB2—urinary bladder cancer	6.3e-06	4.2e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	6.27e-06	4.18e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—IL2—urinary bladder cancer	6.26e-06	4.17e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—TYMS—urinary bladder cancer	6.18e-06	4.12e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—TYMS—urinary bladder cancer	6.13e-06	4.08e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—TP53—urinary bladder cancer	6.13e-06	4.08e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	6.11e-06	4.07e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	6.11e-06	4.07e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CCND1—urinary bladder cancer	6.1e-06	4.06e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	6.06e-06	4.04e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	6.06e-06	4.04e-05	CbGpPWpGaD
Celecoxib—MAPK14—Immune System—HRAS—urinary bladder cancer	5.95e-06	3.96e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MMP9—urinary bladder cancer	5.92e-06	3.95e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—CDKN1A—urinary bladder cancer	5.9e-06	3.93e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—PTEN—urinary bladder cancer	5.89e-06	3.92e-05	CbGpPWpGaD
Celecoxib—ALB—Hemostasis—HRAS—urinary bladder cancer	5.86e-06	3.9e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—GPX1—urinary bladder cancer	5.85e-06	3.9e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—GPX1—urinary bladder cancer	5.8e-06	3.87e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	5.75e-06	3.83e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	5.7e-06	3.8e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—EP300—urinary bladder cancer	5.62e-06	3.74e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—SRC—urinary bladder cancer	5.46e-06	3.64e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	5.4e-06	3.6e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—CDKN1A—urinary bladder cancer	5.38e-06	3.59e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—PTEN—urinary bladder cancer	5.37e-06	3.58e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	5.36e-06	3.57e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PPARG—urinary bladder cancer	5.31e-06	3.53e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—NQO1—urinary bladder cancer	5.21e-06	3.47e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—EP300—urinary bladder cancer	5.12e-06	3.41e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—CREBBP—urinary bladder cancer	5.1e-06	3.4e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—SRC—urinary bladder cancer	4.98e-06	3.32e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—MYC—urinary bladder cancer	4.89e-06	3.26e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—EGFR—urinary bladder cancer	4.79e-06	3.19e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—KRAS—urinary bladder cancer	4.52e-06	3.01e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—PTEN—urinary bladder cancer	4.5e-06	3e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—MYC—urinary bladder cancer	4.46e-06	2.97e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PPARG—urinary bladder cancer	4.38e-06	2.92e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—EGFR—urinary bladder cancer	4.37e-06	2.91e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	4.35e-06	2.9e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PPARG—urinary bladder cancer	4.34e-06	2.89e-05	CbGpPWpGaD
Celecoxib—PTGS2—Metabolism—EP300—urinary bladder cancer	4.29e-06	2.86e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	4.21e-06	2.8e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PTGS2—urinary bladder cancer	4.17e-06	2.78e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	4.17e-06	2.78e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—KRAS—urinary bladder cancer	4.13e-06	2.75e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—TYMS—urinary bladder cancer	4.04e-06	2.69e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—TP53—urinary bladder cancer	4.02e-06	2.68e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	4e-06	2.66e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	4e-06	2.66e-05	CbGpPWpGaD
Celecoxib—MAPK14—Signaling Pathways—HRAS—urinary bladder cancer	3.84e-06	2.56e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—GPX1—urinary bladder cancer	3.83e-06	2.55e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	3.76e-06	2.5e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—PTEN—urinary bladder cancer	3.64e-06	2.42e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	3.53e-06	2.35e-05	CbGpPWpGaD
Celecoxib—PTGS2—Disease—HRAS—urinary bladder cancer	3.51e-06	2.34e-05	CbGpPWpGaD
Celecoxib—ALB—Metabolism—EP300—urinary bladder cancer	3.47e-06	2.31e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	3.45e-06	2.3e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	3.42e-06	2.28e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—PTEN—urinary bladder cancer	3.01e-06	2e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—PTEN—urinary bladder cancer	2.98e-06	1.98e-05	CbGpPWpGaD
Celecoxib—CYP2D6—Metabolism—EP300—urinary bladder cancer	2.87e-06	1.91e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PPARG—urinary bladder cancer	2.86e-06	1.91e-05	CbGpPWpGaD
Celecoxib—CYP2C9—Metabolism—EP300—urinary bladder cancer	2.84e-06	1.89e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	2.75e-06	1.83e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	2.25e-06	1.5e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—PTEN—urinary bladder cancer	1.97e-06	1.31e-05	CbGpPWpGaD
Celecoxib—CYP3A4—Metabolism—EP300—urinary bladder cancer	1.87e-06	1.25e-05	CbGpPWpGaD
